Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) CFO Sean F. Moran acquired 1,500 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average cost of $7.04 per share, with a total value of $10,560.00. Following the purchase, the chief financial officer now owns 340,910 shares of the company’s stock, valued at approximately $2,400,006.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) traded up $0.20 on Monday, hitting $7.25. 936,400 shares of the stock were exchanged, compared to its average volume of 811,531. Corbus Pharmaceuticals Holdings, Inc. has a 1 year low of $5.30 and a 1 year high of $10.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.80 million during the quarter. Corbus Pharmaceuticals Holdings had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. research analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post -0.63 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/13/insider-buying-corbus-pharmaceuticals-holdings-inc-crbp-cfo-purchases-1500-shares-of-stock.html.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Corbus Pharmaceuticals Holdings by 24.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock worth $9,850,000 after acquiring an additional 307,979 shares during the last quarter. State Street Corp lifted its holdings in shares of Corbus Pharmaceuticals Holdings by 2,998.2% in the 2nd quarter. State Street Corp now owns 588,662 shares of the biopharmaceutical company’s stock worth $3,708,000 after acquiring an additional 569,662 shares during the last quarter. Northern Trust Corp raised its holdings in Corbus Pharmaceuticals Holdings by 814.3% during the 2nd quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock valued at $3,039,000 after buying an additional 429,584 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in Corbus Pharmaceuticals Holdings by 4.3% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 444,504 shares of the biopharmaceutical company’s stock valued at $3,178,000 after buying an additional 18,224 shares during the last quarter. Finally, Artal Group S.A. bought a new stake in Corbus Pharmaceuticals Holdings during the 2nd quarter valued at $1,575,000. Hedge funds and other institutional investors own 29.20% of the company’s stock.

A number of research firms have commented on CRBP. Cantor Fitzgerald set a $24.00 price target on shares of Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Noble Financial reissued a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Wednesday, August 9th. BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Finally, ValuEngine cut shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $20.75.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.